Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 9

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Amyotrophic lateral sclerosis

Recruiting

A Study Testing the Safety of LTX-002 Sodium Given into the Spinal Canal in Adults with Amyotrophic Lateral Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LTX-002 SODIUM
  • Sponsor:Leal Therapeutics Inc.

Myotonic dystrophy

Recruiting

A study testing the safety and effects of ADS-019 in adults aged 18 to 65 years with type 1 myotonic dystrophy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:ADS-019
  • Sponsor:Sarepta Therapeutics Inc.

Progressive multiple sclerosis

Recruiting

A study testing ACT-1004-1239 compared to placebo for adults with progressive multiple sclerosis to measure nerve repair using MRI scans

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:ACT-1004-1239
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Cerebral palsy

Recruiting

Study of Cenegermin Nasal Spray for Safety and Tolerability in Children with Spastic Cerebral Palsy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Encephalitis autoimmune

Recruiting

Testing 18F-DPA-714 PET scan as a marker of brain inflammation in patients with autoimmune encephalitis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Parkinson's disease

Recruiting

A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:F. Hoffmann-La Roche AG

Myasthenia gravis

Recruiting

Study of oral cladribine compared to placebo for patients with generalized myasthenia gravis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Merck Healthcare KGaA

Parkinson's disease

Recruiting

A Study Testing SUL-238 in Patients with Early, Untreated Parkinson's Disease to Assess Effects on Brain Energy Metabolism

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.S.

Severe myoclonic epilepsy of infancy

Recruiting

A study using MPPF imaging to examine serotonin pathways in the brainstem of patients with Dravet Syndrome epilepsy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:4-Fluoro-N-[2-[4-(2-Methoxyphenyl)Piperazin-1-Yl]Ethyl]-N-Pyridin-2-Ylbenzamide
  • Sponsor:Hospices Civils De Lyon

Giant cell arteritis

Recruiting

A Study Using [AL[18F]F]FAPI-74 PET Scan to Improve Diagnosis and Monitoring of Giant Cell Arteritis in Patients with This Blood Vessel Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:UZ Leuven

Brain stem glioma+3

Recruiting

Study of ONC206 for children and young adults with newly diagnosed or recurrent diffuse midline glioma and other recurrent brain tumors

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Myasthenia gravis

Recruiting

A Study Comparing Nipocalimab and Efgartigimod for Adults with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Janssen Cilag International

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.